Phase II clinical trial, non-randomized, multicentre, on the combination of gemcitabine, capecitabine and sorafenib (Bay 43-9006) in treatment of patients with unresectable and/or metastatic renal cell carcinoma (RCC).
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2009
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms SOGUG02-06
- 13 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 13 Jan 2009 Acronym identified as SOGUG02-06 as reported by ClinicalTrials.gov.
- 13 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.